Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Mucosal sites serve as the main portal for the entry of pathogens and thus immunization through mucosal routes can greatly improve the immunity. Researchers are continuously exploring the vaccination strategies to engender protective mucosal immune responses. Unearthing of mucosal adjuvants, that are safe and effective, is enhancing the magnitude and quality of the protective immune response. Use of nanotechnology based polymeric nanocarrier systems which encapsulate vaccine components for protection of sensitive payload, incorporate mucosal adjuvants to maximize the immune responses and target the mucosal immune system is a key strategy to improve the effectiveness of mucosal vaccines. These advances promise to accelerate the development and testing of new mucosal vaccines against many human diseases. This review focuses on the need for the development of nanocarrier based mucosal vaccines with emphases on the polymeric nanoparticles, their clinical status and future perspectives. This review focuses on the need and new insights for the development of nanoarchitecture governed mucosal vaccination with emphases on the various polymeric nanoparticles, their clinical status and future perspectives.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.biotechadv.2014.12.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chitosan-based Oral DNA vaccine elicits mucosal immunity and reduces Helicobacter pylori colonization in mice.
Vaccine
September 2025
Department of Biological Science and Technology, National Yang Ming Chiao Tung University, Hsinchu, Taiwan.
Oral vaccination offers a promising strategy for controlling Helicobacter pylori infection, particularly in the face of rising antibiotic resistance and reinfection rates. In this study, we developed a chitosan nanoparticle-mediated oral DNA vaccine encoding the urease B subunit of H. pylori.
View Article and Find Full Text PDFEvaluation of the efficacy of polymeric antigen BLSOmp31 formulated in a new cage-like particle adjuvant (ISPA YOLK) administered by parenteral or mucosal routes against Brucella ovis in rams.
Vet Immunol Immunopathol
September 2025
Laboratorio de Inmunología, Departamento de Sanidad Animal y Medicina Preventiva (SAMP), Centro de Investigación Veterinaria Tandil (CIVETAN-CONICET-CICPBA), Facultad de Ciencias Veterinarias (FCV), Universidad Nacional del Centro de la Provincia de Buenos Aires (UNCPBA), Tandil, Buenos Aires, Arg
Brucella ovis (B. ovis) is the etiological agent of ram-contagious epididymitis, the leading cause of reproductive disorders in flocks worldwide. Although the attenuated B.
View Article and Find Full Text PDFEvaluation of the C protein of BVDV as a vaccine candidate: Immunoprotective studies in mice.
Vet Microbiol
September 2025
College of Animal Science and Technology/Laboratory of Functional Microbiology and Animal Health, Henan University of Science and Technology, Luoyang 471023, PR China; Luoyang Key Laboratory of Live Carrier Biomaterial and Animal Disease Prevention and Control, Henan University of Science and Techno
Bovine Viral Diarrhea Virus (BVDV) is a major pathogen associated with calf diarrhea and reproductive disorders in cattle. This study evaluated the immune-protective potential of a subunit vaccine based on the capsid C protein of the BVDV HNL-1 strain. In mice model, the C protein subunit vaccine exhibits a favorable safety and elicits robust immune-protective efficacy comparable to commercial inactivated vaccines.
View Article and Find Full Text PDFThe Role of Enoxaparin in Influenza Virus Infections and Its Therapeutic Implications.
J Infect Dis
September 2025
University of Veterinary Medicine Vienna, Infectiology, Vienna, Austria.
Frequent emergence of respiratory viruses with pandemic potential, like SARS-CoV-2 or influenza, underscores the need for broad-spectrum prophylaxis. Existing vaccines show reduced efficacy against newly emerged variants, and the ongoing risk of new outbreaks highlights the importance of alternative strategies to prevent infection and viral transmission. As respiratory viruses primarily enter through the nose, formulations targeting the nasal epithelium are attractive candidates to neutralize pathogens and thus prevent or minimize infection.
View Article and Find Full Text PDFNanotechnology-driven strategies for tilapia vaccines: Comparative evaluation of nanoemulsions and silica nanoparticles against .
Vet World
July 2025
Research Center for Veterinary Science, National Research and Innovation Agency, Jl. Raya Bogor Km. 46 Cibinong, Bogor, 16911, West Java, Indonesia.
Streptococcosis, caused by , is a significant disease in tilapia farming that results in substantial economic losses. While vaccination is the most effective method for prevention, current vaccines face challenges when administered orally or through immersion, primarily due to poor absorption and degradation in the fish's digestive system. Nanotechnology offers new ways to improve vaccine delivery and effectiveness.
View Article and Find Full Text PDF